Indian Pharma Market registers 12.1% growth in February 2020
The Indian Pharmaceutical Market (IPM) has registered a growth of 12.1% for the month of February 2020, recovering from the lower growth in January 20, which stood at 7.7%. The growth is essentially led by the top therapies.
According to AIOCD AWACS report, the IPM has recorded sales of Rs. 1,42,658 crore and a growth of 9.7 per cent for Moving Annual Total (MAT) basis during February 2020.
Among the top 50 corporates, 37 exhibited double digit growth, with an average of 16.84%, while 2 of the top 50 corporates registered degrowth for the month of February, 2020.
Amongst the top 10 corporates, Macleods showed the highest growth of 21.41%, followed by Mankind at 19.06%, Torrent at 17.35%, Sun Pharma at 14.44%, Intas at 14.01%, Alkem at 13.58%, Lupin at 13.37%, Zydus at 11.70% and Cipla at 10.40%. Only Abbott was among top 10 corporates growing at less than 10% (9.36%).
Amongst the corporates ranked 11-20, Aristo exhibited the highest growth of 25.44%, followed by Dr. Reddy's growing at 21.42%, Micro at 18.02%, USV at 16.65%, Glenmark at 15.59%, Emcure at 14.65%, Pfizer at 14.1%, Ipca at 12.15% and Sanofi at 10%. While only GSK growing at less than 10% (7.85%).
Amongst the corporates ranked 21-30, Natco exhibited the highest growth of 24.71%, FDC growing at 18.29%, followed by Franco at 16.94%, Eris at 16.27% and Cadila Pharma at 14.65%. While rest of the corporates growing at less than 10%.
Amongst the 31-40 ranked corporates, BI exhibited highest growth of 27.74%, followed by La Renon at 20.86%, Blue Cross at 19.64%, Medley at 19.57%, Ajanta at 14.38%, JB Chemicals at 13.93% and Bharat Serums at 10.94%. While MSD registered a degrowth of (-4.49%).
Amongst the 41-50 ranked corporates, Corona growing at 25.09%, followed by Wallace at 19.69%, Hegde & Hegde at 19.03%, Fourrts at 16.59%, Win Medicare at 14.42% & Systopic at 11.16%. While rest growing less than 10%.
Amongst the corporates ranked 51-60, Danone growing at 37.72%, followed by Fresenius at 29.41%, Pharmed at 20.47%, Centaur at 17.73%, Raptakos at 17.71%. While rest growing less than 10%. Troikaa, Biocon & Allergan registering degrowth.
Amongst the corporates 61-70, Koye Pharma registering a growth of 35.41%, followed by Eli Lilly at 22.80%, Serum Institute at 22.08% & East India by 21.75%. While Akumentis and Mylan registering degrowth.
Corporates ranked amongst 71-80, Tablets India leading with 15.40%, followed by Biological E at 13.3%, Samarth at 13.31%, Unimed TL at 11.68%, Modi Mundi at 10.53% and Oaknet Healthcare at 10.27%. while rest growing less than 10%.
Amongst the corporates ranked 81-90, Charak exhibited highest growth of 26.55% and Walter Bushnell at 11.70%. Most of the corporates growing at less than 10%, while Shreya, Torque and Geno Pharma degrowing.
Amongst the corporates ranked 91-100, Finecure Pharma registers growth of 37.53%, Linus Lab at 26.82%, Alniche Life Sciences at 21.29%, Unison at 18.31, and Med Manor at 12.92%. While AIMIL, Roche and Lincoln degrowing.
Amongst the ranked 101-150, below corporates growing at double digit-Indiabulls Pharmaceuticals, Zandu, Reckitt Benckiser, Lloyd Hc, Juggat, Kepler Hc, Brinton Pharma, Fusion Healthcare, Elan, Vanguard, Johnson & Johnson, Icpa, Menarini India, Aksigen, Talent India, Nulife, Deys Medical, Dwd, Meridian, Comed, Mapra.
Among the top 10 companies, all have registered growth of more than 10%, with highest being Macleods at 21.41% and lowest being Cipla at 10.4%.
For the month of February, multinational companies exhibiting a growth of 7.6%, 5.2% for the quarter and 8.3% for the MAT period. While the Indian corporates exhibiting 13.2% for the month, 10.6% for the quarter and 10% for the MAT.
Amongst the top MNCs, Boehringer Ingelheim 24.74% exhibited the highest growth followed by Eli Lilly at 22.8%.
About 44 corporates launched in the past 36 months that show some sale and only 1 company have crossed the 10 crore mark in annual sales (MAT Feb 20).
Among the top brands, Mixtard has maintained the top position for the month of February 20. While Lantus has lost a position and moved to no.3, while Glycomet-GP has moved up to no.2. Janumet has moved up to no.4 and Augmentin to no.5 position.
Few major brands, who have dropped in ranks on MAT basis- Galvus Met lost 6 ranks, Phensedyl Cough Linctus (-4), Istamet (-7), PanD (-8), Volini (-2), Gluconorm G (-6), Shelcal (-4).
From therapy (Super Group) perspective on MAT basis, 9 of the 20 therapies are reflecting a growth in double digit. Highest among that being stomatologicals 15.9% followed by blood related 15.3%, urology 14.1%, sex stimulants 13.8%, respiratory at 11.5%, cardiac and anti-diabetic at 11% each and hormones at 10.1%, anti infectives 9.9%, pain and analgesics 9.6%, neuro/CNS 9.4%, vitamins & minerals 9.1%, opthal 8.3%, GI at 8.1%, derma at 7.8%, anti-neoplastic 7.5%, gynaecology 7.3%, and vaccines 6.9%.
There were 282 (576 SKUs) brands launched in the month of Feb 20, which has added Rs. 8.06 crore incremental sales to the market.
Comments
Post a Comment